Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosion Cleared to Start US Trials of Novel anti-SIRPα mAb for Solid Tumor Cancers

publication date: Jan 31, 2024

Biosion USA, an arm of Nanjing Biosion, has been cleared to begin US trials of BSI-082, a novel anti-SIRPα mAb targeting solid tumor cancers. BSI-082 blocks the interaction of SIRPα to CD47, the "don't eat me" signal expressed on many tumors. By blocking SIRPα, the candidate enables macrophages and dendritic cells to resume their assault on tumor cells while avoiding the toxicity of many CD47-targeting therapies, according to the company. Biosion has sold China rights for the candidate to Chia Tai Tianqing Pharma (CTTQ), which has started a Phase I trial of BSI-082 in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital